IP Library Granted Patent US 7,319,019
Granted Patent B1
US 7,319,019 · App. 08/734,665 · Granted Jan 15, 2008

Glial mitogenic factors lacking an N-terminal signal sequence

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,319,019
App. No.
08/734,665
Granted
Jan 15, 2008
Kind
B1
Abstract

Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Also included is the mature GGF peptide and the DNA encoding said peptide, exclusive of the N-terminal signal sequence. The mature GGF peptide and DNA encoding the same are also useful for treatment of conditions of the central nervous system. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.

Claims (9)

1. An isolated DNA molecule encoding a GGF/p185 erbB2 ligand polypeptide having Schwann cell mitogenic activity, wherein said DNA molecule comprises nucleic acids encoding an EGF-like domain comprising EGFL 2 (SEQ ID NO: 200), EGFL 4 (SEQ ID NO: 202), EGFL 5 (SEQ ID NO: 203), or EGFL 6 (SEQ ID NO: 204).

2. An isolated DNA molecule encoding a GGF/p185 erbB2 ligand polypeptide having Schwann cell mitogenic activity, wherein said DNA molecule comprises nucleic acids encoding an EGF-like domain consisting of EGFL 2 (SEQ ID NO: 200), EGFL 4 (SEQ ID NO: 202), EGFL 5 (SEQ ID NO: 203), or EGFL 6 (SEQ ID NO: 204).

3. An isolated DNA molecule encoding a polypeptide factor comprising the amino acids 51 to 422 of SEQ ID NO: 170, and lacking amino acids 1-50 of SEQ ID NO: 170.

4. A vector comprising the DNA molecule of claim 1 .

5. An isolated host cell containing the isolated DNA molecule of claim 1 .

6. A method for the preparation of a glial cell GGF/p185 erbB2 mitogenic factor, said method comprising a) cultivating the host cell of claim 4 , under conditions permitting expression of said DNA molecule, and b) isolating said mitogenic factor.

7. An isolated DNA molecule encoding a GGF/p185 erbB2 ligand polypeptide having Schwann cell mitogenic activity, wherein said DNA molecule consists of nucleic acids encoding amino acids 362-411 of SEQ ID NO:170.

8. An isolated DNA molecule encoding a GGF/p185 erbB2 ligand polypeptide having Schwann cell mitogenic activity, wherein said DNA molecule consists of nucleic acids encoding amino acids 358-422 of SEQ ID NO: 170.

9. An isolated DNA molecule encoding a GGF/p185 erbB2 ligand polypeptide having Schwann cell mitogenic activity, wherein said DNA molecule consists of nucleic acids encoding EGFL 3 (SEQ ID NO: 201).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2003
From: CENES PHARMACEUTICALS, INC.
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 013943/0249 →
CHANGE OF NAME Recorded May 21, 2001
From: CAMBRIDGE NEUROSCIENCE, INC.
To: CENES PHARMACEUTICALS, INC.
Reel/Frame 011812/0784 →